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When a clear sequence of events is available, as in the present case, the risk of antipsychotics combined with carbamazepine/ oxcarbazepine leading to SIADH or polydipsia 19 should be seriously evaluated upfront, especially in a patient with genetic epilepsy who is at increased risk due to a supratherapeutic carbamazepine therapy. To prevent electrolyte imbalances, a cheap and feasible strategy comprises routine blood examinations, therapeutic drug monitoring, and the monitoring of patients' water intake because polydipsia may be an important pathological marker. This grants the opportunity to detect subtle electrolyte changes that may otherwise go unnoticed until they have a clinically relevant impact. Proper monitoring should be always performed as a precaution because subclinical hyponatremia may also reduce neuropsychological performances. 20 The present case is an example of how 2 drugs with a low-risk potential synergized to produce an adverse reaction. The risk of developing an ADR in this patient went unnoticed; because she never displayed polydipsia, detection of the ADR was virtually impossible without an accidental blood examination. Proper drug monitoring and knowledge of drug-specific risks of ADRs may prevent seizure precipitation due to electrolyte imbalances and should be encouraged as part of an optimal clinical practice. However, pharmacokinetic evidence does not support an inhibiting effect of MET on CYP3A4/5 activity. 3 Alternatively, dosedependent pharmacokinetic patterns may offer explanatory models for the discrepancy between case reports and in vivo studies. 4 In vitro findings imply an inhibiting effect of MET on CYP2C9, but not on CYP2D6. 5, 6 However, the mechanism by which MET alters the disposition of different drugs including tacrolimus, amiodarone, cyclosporine, carbamazepine, and quinidine 3 remains unclear so far; it might also be a result of its influence on transport proteins such as p-glycoprotein, although data do not support an inhibiting effect on p-glycoprotein hitherto. 7, 8 Hence,
AUTHOR DISCLOSURE INFORMATION
DDIs between MET and a number of drugs have to be further elucidated because they may be the result of various processes including alterations in absorption, distribution, metabolism, and excretion of the affected drug. In addition, inflammatory conditions may be associated with CYP inhibition 9 and particularly with an inhibition of risperidone (RIS) metabolism. 10, 11 Researchers suggested that the underlying mechanism might include CYP3A4, glucuronosyltransferases, or drug efflux transporters. 10 In this regard, therapeutic drug monitoring (TDM) can be used to optimize patient-oriented pharmacotherapy helping to disentangle DDIs in clinical settings. Therefore, we report a clinically interesting case in which the addition of MET to an ongoing treatment with RIS and venlafaxine (VEN) led to an unexpected increase of the serum levels and a change in the relation between the parent compound and the metabolites (altering the so-called metabolic ratio) of both psychotropic drugs.
CASE REPORT
Mrs L is an 81-year-old inpatient diagnosed with a recurrent major depressive disorder with psychotic symptoms (ICD-10: F33.3) including delusion of poisoning. She was hospitalized in the Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Aachen, Germany, and was initially treated with nortriptyline 75 mg and RIS up to 2 mg. This was the therapeutic regimen at the time of admission. Because of a lack of response in the outpatient setting, VEN was started in daily dosages up to 187.5 mg, RIS dosage was increased up to 4 mg, and nortriptyline was stopped. The patient had been already under this therapeutic regimen for a week when she was diagnosed with a nosocomial infection of the urinary tract. Cefuroxime was added for an antimicrobial therapy. Hereafter, a Clostridium difficile-associated diarrhea occurred, and an antimicrobial therapy with MET in a daily dosage of 1,200 mg (in 400 mg tablets) was initiated, and routine examinations including TDM were performed regularly. The clinical condition was marked by exsiccosis and general exhaustion on the day when MET was started. The laboratory revealed a C-reactive protein (CRP) enhancement up to 70.2 mg/mL (reference range, <5 mg/mL) but normal leucocytes. Furthermore, starting from initially normal serum sodium levels, a hyponatremia with a level of 129 mmol/L (reference range, 136-145 mmol/L) occurred 2 days after the MET therapy initiation, whereas no changes in electrocardiogram results were observed (QT C 441 milliseconds). At this point, renal function parameters were normal.
Two weeks before the start of the antimicrobial treatment, the serum level for the so-called active moiety (AM) (sum of RIS + 9-hydroxyrisperidone [9-OH-RIS]) was 77.9 ng/mL and higher as the therapeutic reference range of 20 to 60 ng/mL. 12 Nonetheless, the daily dosage of 4 mg remained unchanged. At this moment, it had been only 3 days after initiation of VEN therapy and daily dosage was low; thereby, TDM did not include VEN. After starting the MET treatment (on day 0), serum levels of the AM were raised up to 225 ng/mL (Table 1) and exceeded the upper threshold of the therapeutic reference range nearly fourfold. Serum concentrations of VEN and O-desmethylvenlafaxine (ODV) were found to be unusually high after starting MET. The AM (VEN + ODV) was found to be 1382 ng/mL and exceeded the upper threshold of the therapeutic reference range for VEN (100-400 ng/mL) more than threefold. 12 Although serum levels for both psychotropic drugs were very high, no signs of intoxication or severe adverse effects could be observed. Only the low blood pressure and intermittent nonvertiginous dizziness, associated with headache, were clinically evident. Revealing the decrease in sodium serum levels and the high drug concentrations justified an adjustment of the therapeutic regimen, and the applied daily dosages were reduced. However, the patient was transferred to an internal ward because of continuing diarrhea. One week later, she was released home with the discharge diagnoses of clostridial enteritis and urinary tract infection caused by Pseudomonas aeruginosa. The discharge therapeutic regimen consisted of RIS 4 mg and VEN 75 mg. Aside from the psychopharmacological treatment, the patient received an antimicrobial therapy with vancomycin 750 mg 
DISCUSSION
The primary pathway of RIS metabolism is a CYP2D6-catalyzed 9-hydroxylation, and the main active metabolite is 9-OH-RIS. Furthermore, in vitro findings have revealed that CYP3A4 and CYP3A5 might be also involved in the metabolism of RIS. 13 Risperidone and 9-OH-RIS exhibit differences in 5-HT 2A /D 2 (serotonin/dopamine) binding ratios, show differences in plasma-protein binding (90% vs 74%) and in terminal half-life time (3 hours for RIS vs 23 hours for 9-OH-RIS). For RIS, 2 TDM measures have received particular attention 14 ; the ratio RIS/9-OH-RIS is considered as a reliable measure of CYP2D6 metabolic activity, and the AM (RIS + 9-OH-RIS) divided by the RIS dosage (total concentrationby-dose ratio in [ng/mL]/[mg/d]) is considered to sufficiently reflect the total clearance of RIS. If the latter is increased in the absence of an increase in RIS/9-OH-RIS, it may be a sign of CYP3A4 inhibition. Venlafaxine is principally metabolized not only by CYP2D6 to ODV, its major active metabolite, but also by CYP3A4 to the inactive metabolite N-desmethylvenlafaxine, and, to some degree, CYP2C19 and CYP2C9 play a role in the metabolism of VEN too. When comparing VEN with other antidepressants, it is reported to show a low protein binding (27% for VEN and 30% for ODV). 15 Of clinical interest are the differences between VEN and ODV regarding their half-life (5 and 11 hours) as well as renal excretion (5% and 30%). 16 The ratio ODV to VEN provides valuable information for the metabolizer status, 17 12 as the so-called dose-adjusted plasma or serum concentration. There is a previously described pharmacokinetic interaction between VEN and RIS via CYP2D6 because VEN is a weak inhibitor of 2D6 leading to higher concentrations of RIS and to a decrease in renal elimination of 9-OH-RIS. 18 The metabolism of MET is independent from CYP2D6 activity, 19 and the main metabolic pathway involves CYP2A6. No pharmacokinetic interactions between MET and RIS or MET and VEN are previously described. Of specific interest is the spectacular increase in blood levels and particularly active metabolites of both psychotropic drugs; this implies an effect of METon both drugs rather than a cascade of pharmacokinetic changes. However, pharmacokinetic interactions via the cytochrome system do not sufficiently account for the increase of drug concentrations of RIS, 9-OH-RIS, VEN, and ODV after the addition of MET. Moreover, there were no hints of renal impairment. Therefore, it remains unclear why, in the case of 9-OH-RIS and ODV, the patient was not able to eliminate the metabolites. It might be seen as a complex pharmacokinetic interaction and/or the consequence of the inflammatory condition. Nevertheless, in our case, an inhibitory effect of inflammation is not clearly demonstrated because the temporal course of CRP values did not match the course of the drugs' serum levels. Knowledge of CYP2D6 and CYP2C19 genotypes would undoubtedly shed light on the mechanism underpinning the interaction reported here. However, genetic tests of CYP activity for polymorphic cytochrome enzymes are still not established in clinical routine, and this option was not available in our case hampering a better understanding of this evidence.
Our case underscores the usefulness of TDM for treatment optimization and improvement of patients' safety. Luckily, except orthostatic hypotension and dizziness, no other clinically relevant adverse effects could be observed. The mentioned undesirable effects partly subsided after reducing the daily dosage of RIS and VEN. Our case report highlights the benefits of TDM application in clinical routine as an alarm for individual abnormalities such as DDIs essentially helping to prevent negative outcomes.
Olanzapine Long-Acting Injections After Neuroleptic Malignant Syndrome Two Case Reports
To the Editors:
N euroleptic malignant syndrome (NMS) is a rare, unpredictable, but potentially life-threatening condition associated with antipsychotic use. It is characterized by rigidity, tremor, fever, alterations of mental status, leukocytosis, and creatine kinase (CK) elevation. 1 Although more than half of all reported NMS cases are associated with haloperidol, it is associated with virtually all antipsychotics. 2 Patients with schizophrenia need to be treated after recovery from NMS, but they are at an elevated risk of developing NMS after future exposure to antipsychotics. The data regarding antipsychotic treatment after NMS are sparse. Low-potency antipsychotics are recommended, including clozapine 3 and quetiapine. 1, 3 Both drugs are available only in oral formulations. Longacting injectable (LAI) antipsychotics are recommended for nonadherent patients with schizophrenia, and they showed superiority compared with oral antipsychotics in preventing hospitalizations. 4 There are no data of treatment with LAI antipsychotics after the resolution of NMS, and sustained high level of dopamine D2 receptor occupancy might induce the recurrence of NMS. Olanzapine LAI was associated with D2 receptor occupancy of approximately 60%. 5 Other LAI antipsychotics including haloperidol decanoate and risperidone LAI 6,7 occupy a higher percentage of dopamine D2 receptors. There are currently no data for paliperidone and aripiprazole LAIs.
Given that olanzapine was recommended as a safe and effective option after NMS 8 and the relatively low occupancy of dopamine D2 receptors with olanzapine LAI, 5 we present 2 patients, known to be nonadherent with antipsychotics, who were treated with olanzapine LAI after the resolution of NMS.
In both patients, diagnosis of schizophrenia and NMS was established according to criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (published by the American Psychiatric Press, 1994).
CASE REPORTS Case 1
A 30-year-old woman has been treated for schizophrenia for 9 years. She had several episodes of nonadherence to medication. For the last 3 years, she was receiving risperidone LAI 50 mg twice monthly, combined with oral risperidone 4 mg daily. Because the patient was in good remission, oral risperidone was withdrawn. Several months before admission, she was receiving only risperidone LAI, twice monthly. Despite regular applications, her condition worsened in terms of agitation, paranoid delusions, insomnia, and disorganized thinking and behavior, resulting in emergency hospitalization. Upon admission, short-acting muscular haloperidol was applied, followed by oral haloperidol 15 mg daily for the next 9 days. For the next 6 days, haloperidol dose was reduced to 6 mg daily, and risperidone was instituted at the dose of 6 mg daily. The patient developed fever (highest temperature, 38.6°C), muscular rigidity, tremor, elevated CK levels (highest value, 3486 U/L; reference range, 0-177 U/L), altered consciousness, tachycardia (highest rate, 123), dysarthria, and dysphagia. Antipsychotics were discontinued, and she was transferred to the intensive care unit where she stayed for 2 weeks. Although fever resolved and CK levels normalized, the patient developed catatonia, presenting with negativism, mutism, and occasional episodes of uncontrolled motor restlessness. She was admitted in our department for electroconvulsive therapy, where she received 12 applications and her condition improved. In addition, oral olanzapine was started, with slow and careful titration up to 20 mg daily. Because treatment with olanzapine was both safe and effective and the risk of nonadherence was high, olanzapine LAI 300 mg twice monthly was instituted. The patient has been receiving olanzapine LAI at the same dose for 15 months, with 10 mg of oral olanzapine twice daily and 1500 mg of valproate to treat occasional mood swings. Functional remission is achieved, and the patient is working full time. Olanzapine concentration was 323.1 nmol/L before LAI injection and 251.0 nmol/L 3 hours after the most recent injection (reference range, 64-256 nmol/L). However, the patient received oral olanzapine at 7:00 AM, and the first sample was taken at 1:00 PM. This corresponds to maximal concentration after oral olanzapine intake.
